Leukemia and Lymphoma

The AJMC® Leukemia & Lymphoma compendium is a comprehensive resource for clinical news and expert insights for the blood cancers and their treatments.

Phase 3 Study: Zanubrutinib Improves PFS Over Chemoimmunotherapy in Untreated CLL, SLL

August 4th 2022, 7:41pm


The findings, coming from the phase 3 SEQUOIA study, found that the next-generation, selective Bruton tyrosine kinase inhibitor had superior efficacy versus chemoimmunotherapy and demonstrated an acceptable safety profile among 600 older patients with comorbidities.

For Early-Stage cHL Survivors, CVD Has Surpassed Neoplasms as Leading Cause of Death

August 3rd 2022, 7:37pm


Cardiovascular disease (CVD) has, over time, becoming the leading cause of death for patients with early-stage classic Hodgkin lymphoma (cHL), surpassing the risk of death from cHL and other cancers.

Dr Susan Escudier: OCM Improvements That Practices Should Continue

July 29th 2022, 1:49pm


Even though the Oncology Care Model (OCM) ended on June 30, 2022, there are some improvements that practices should continue implementing, said Susan Escudier, MD, FACP, vice president of value-based care and quality programs, Texas Oncology.

Venetoclax May Restore Function in CD4 T Cells in CLL

July 9th 2022, 1:16pm


Researchers of this new study found that treatment with venetoclax may be able to restore activation and proliferation of these cells, suggesting their plasticity can be leveraged for autologous T-cell–based treatments.

Novel Mechanism of Resistance to Venetoclax Identified in CLL, Lymphoma

July 6th 2022, 9:25pm


Researchers have found that resistance to the BCL2 inhibitor was driven by methylation and epigenetic silencing of PUMA.

Palliative Care Shortcomings for Patients With Hematologic Malignancies Addressed in New Review

June 26th 2022, 11:10am


A recent review explored current palliative care practices for patients with hematologic cancers compared with solid tumor cancers.

Study Shows Significant Disparities in Worldwide Rates of Non-Hodgkin Lymphoma

June 22nd 2022, 11:12am


Recent research used incidence and mortality data from the GLOBOCAN 2020 database to gain insight into worldwide patterns of non-Hodgkin lymphoma in 2020.

Challenging the “One-Size-Fits-All” Approach in Early MCL Treatment

June 19th 2022, 10:30am


Anita Kumar, MD, medical oncologist with Memorial Sloan Kettering Cancer Center, led a session at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO), on New Directions in Mantle Cell Lymphoma.

Dr Mazyar Shadman Highlights the Challenges of Subgroup Analysis When Trials Lack Diversity

June 16th 2022, 1:02pm


Increased diversity in clinical trials remains an unmet need, and in the new SEQUOIA trial, the majority of patients being White males meant researchers could not do a subgroup analysis looking at outcomes for specific races, age groups or genders, said Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Research Center.

Parental Age May Be Linked With Childhood Cancer Risk, but More Research Is Needed

June 14th 2022, 12:00pm


A recent meta-analysis aimed to clarify the relationship between parental age and solid tumor pediatric cancers, but more studies are necessary to overcome the limitations of available research.